Reduces hetero-transplanted tumours in hamsters
1965 Riga Virotherapy laboratory
Aina Muceniece MD, Dr. habil. med., Head
1968 Clinical trials start in Latvia
Safety & efficacy
1985 Extended clinical trials in Latvia
1987 Multicenter, multinational clinical trials
1991 Latvia regains its independence
2002 Rigvir® receives a patent
2004 Rigvir® approved & registered in Latvia
2015 Rigvir® approved & registered in Georgia
2016 Rigvir® approved & registered in Armenia
2016 The first cancer virotherapy excellence center, Global Virotherapy Cancer Clinic, is opened.
2016 Rigvir® manufacturer receives a grant from the European Commission’s “Horizon 2020″ with the intended goal of eventually registering the medication in the European Union (EMEA).
2017 Rigvir® manufacturer receives a special recommendations for medication registration in EU from European Medicines agency (EMA).
2017 Rigvir® manufacturer receives Seal of Excellence award given by European Commission within the case of “Horizon 2020” program.
2017 Rigvir® manufacturer receives intellectual property award “WIPO Enterprise Trophy”.